New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
AMRNDUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular risk reduction; a pivotal moment that underscores the need for more effective, evidence-based approaches to residual CV risk.
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
AMRN(NASDAQ:AMRN) -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
AMRN(NASDAQ:AMRN) -- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT --
DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three sub-analyses from the REDUCE-IT® trial describing the impact of VASCEPA®/VAZKEPA® (icosapent ethyl - IPE) administration on cardiovascular disease (CVD) risk associated with Cardiovascular-Kidney-Metabolic (CKM) syndrome, major adverse cardiovascular events (MACE) stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride rich lipoprotein cholesterol (TRL-C) levels, and on hospitalizations. All three post hoc analyses showed significant reductions in cardiovascular risk and outcomes in the populations studied. The data was presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain.
Applications open for Ameren bill payment assistance
AMRNAmeren Illinois customers have received nearly $58 million this year for bill assistance; new program offers additional support COLLINSVILLE, Ill., Aug. 25, 2025 /PRNewswire/ -- Income-qualified customers who have fallen behind on their energy bills can apply for payment assistance from...
Amarin Corp Q1 Adj. EPS $(0.02) Beats $(0.57) Estimate, Sales $42.02M Miss $50.75M Estimate
AMRNExploring Amarin Corp's Earnings Expectations
AMRNAmarin Regains Compliance With Nasdaq Minimum Bid Price Requirement; Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing
AMRNTop 2 Health Care Stocks That May Crash This Month
AMRNGoldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $7
AMRNTrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
AMRNTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
AMRNAmarin Highlights Recent Data Presented At ACC.25 Evaluating Mechanistic Effects Of Eicosapentaenoic Acid In Lp(a)-Enriched Plasma And In Combination With GLP-1 Agonist
AMRNAmarin Says Continuing To Explore All Strategies To Accelerate Growth In Europe Region
AMRNAmarin Intends To Effect Ratio Change On ADSs From One ADS Representing One Ordinary Share To New Ratio Of One ADS Representing 20 Ordinary Shares
AMRNAmarin To Effect An ADS Ratio Change From 1 ADS Representing 1 Ordinary Share To 1 ADS Representing 20 Ordinary Shares (1-For-20)
AMRNAmarin Corp Q4 2024 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $62.31M Beat $35.92M Estimate
AMRNAmarin Published Data In Journal Of The American Heart Association Showing Post-Hoc Analysis Of REDUCE-IT Study Among Statin-Treated Patients With Elevated Triglycerides And High Cardiovascular Risk, VASCEPA/VAZKEPA
AMRNTop 3 Health Care Stocks You'll Regret Missing In Q4
AMRNMid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
AMRNU.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision.
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
AMRNU.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
AMRNU.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.
Why Amarin Shares Are Plunging After Q1 Earnings
AMRNAmarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations.
Recap: Amarin Corp Q1 Earnings
AMRNAmarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Amarin Will Continue To Suspend FY22 Sales Guidance
AMRNAmarin Corp Q1 Adj. EPS $(0.06) Misses $(0.02) Estimate, Sales $94.60M Miss $128.37M Estimate
AMRNAmarin Corp's Earnings: A Preview
AMRNAmarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Amarin Corp will report an earnings per share (EPS) of $-0.02.
